InsiderSignalSign in

← Insider buys

REPL

Replimune Group, Inc. · Healthcare

Insiders sold $1.8M of Replimune Group, Inc. in the last 12 months and bought none

$0Bought, 12 mo

$1.8MSold, 12 mo

$1.1BMarket cap

REPL over the last year

No insider buys filed in this year

REPL after insider buys

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Every filing

114 insider filings since 2018, newest first

Omega Fund Iv, L.P. · Director and 10% owner

Omega Fund Iv, L.P. · Director and 10% owner

Omega Fund Iv, L.P. · Director and 10% owner

Omega Fund Iv, L.P. · Director and 10% owner

$1.0M−1.0%Nov 8

Colin Love · COO

$902K−4.0%Oct 19

Omega Fund Iv, L.P. · Director and 10% owner

Omega Fund Iv, L.P. · Director and 10% owner

$3.3M−2.0%Sep 20

Colin Love · COO

$937K−4.0%Sep 17

Colin Love · COO

$898K−4.0%Aug 18

Pamela Esposito · Chief Business Officer

$1.1M−12.0%Aug 6

Pamela Esposito · Chief Business Officer

$577K−8.0%Jul 22

Pamela Esposito · Chief Business Officer

$154K−2.0%Jul 19

Pamela Esposito · Chief Business Officer

$2.4M−24.0%Jul 19

Colin Love · COO

$961K−3.0%Jul 16

Robert Coffin · Pres, Chief R, D Officer

Robert Coffin · Pres, Chief R, D Officer

$1.5M−2.0%Jun 30

Colin Love · COO

$1.0M−3.0%Jun 16

Colin Love · COO

$919K−3.0%Apr 19

Colin Love · COO

$1.0M−3.0%Mar 17

Colin Love · COO

$1.1M−3.0%Feb 18

Omega Fund Iv, L.P. · 10% owner

Jason P Rhodes · Director

Omega Fund Iv, L.P. · Director and 10% owner

$1.4M−1.0%Jan 28

Robert Coffin · Pres, Chief R, D Officer

$2.7M−3.0%Jan 26

Omega Fund Iv, L.P. · Director and 10% owner

Philip Astley-Sparke · CEO

$2.2M−4.0%Jan 19

Colin Love · COO

$1.3M−3.0%Jan 19

Omega Fund Iv, L.P. · Director and 10% owner

Jean M. Franchi · CFO

$668K−100.0%Jan 15

Robert Coffin · Pres, Chief R, D Officer

$8.8M−11.0%Dec 28

Jason P Rhodes · Director

$181K−18.0%Dec 22

Jason P Rhodes · Director

$2.7M−77.0%Dec 17

Jean M. Franchi · CFO

$1.1M−100.0%Dec 16

Jason P Rhodes · Director

$4.5M−82.0%Dec 14

Philip Astley-Sparke · CEO

$2.2M−4.0%Dec 11

Colin Love · COO

$1.3M−3.0%Dec 11

Jason P Rhodes · Director

$10.0M−88.0%Dec 9

Joseph P Slattery · Director

$239K−44.0%Dec 9

Kapil Dhingra · Director

$1.8M−100.0%Dec 9

Colin Love · COO

$674K−1.0%Nov 18

Pamela Esposito · Chief Business Officer

$526K−12.0%Oct 16

Colin Love · COO

$359K−1.0%Sep 17

Pamela Esposito · Chief Business Officer

$135K−4.0%Sep 1

Colin Love · COO

$352K−1.0%Aug 18

Robert Coffin · Pres, Chief R, D Officer

$3.8M−8.0%Jul 10

Robert Coffin · Pres, Chief Res, Dev Officer

$413K−1.0%Feb 24

Robert Coffin · Pres, Chief Res, Dev Officer

$826K−2.0%Feb 14

Philip Astley-Sparke · Executive Chair

$493K−2.0%Nov 8

Colin Love · COO

$383K−2.0%Nov 8

Robert Coffin · President and CEO

$825K−2.0%Nov 8

Newer filings Older filings

About Replimune Group, Inc.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.